Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 18
  1. May 15, 2026 · 06:30 · PRN · Routine +

    Profound Medical Corp.

    Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

    01
  2. May 14, 2026 · 18:00 · RX · Routine +

    BioSyent’s Q1 Shows Oral Science Deal Paying Off, but Pharma Core Holds Steady

    BioSyent Releases Financial Results for First Quarter 2026

    02
  3. May 14, 2026 · 17:00 · AIAI · Routine +

    NetraMark Secures Capital Runway Amidst Slow Revenue Conversion and Backlog Growth

    NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

    03
  4. May 14, 2026 · 17:00 · DHT · Routine +

    Record royalty income fails to lift DRI Healthcare shares as investors gauge KalVista buyout impact

    DRI Healthcare Reports First Quarter 2026 Results

    04
  5. May 14, 2026 · 16:05 · NRX · Routine +

    NurExone’s EU Program Nod Underscores Exosome Platform’s Promise, But Cash Burn Keeps Investors on Edge

    NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026

    05
  6. May 14, 2026 · 13:48 · CTX · Routine +

    Crescita shareholders overwhelmingly back ClinActiv buyout, paving the way for a clean exit at the premium offer.

    Crescita Obtains Shareholder Approval To Be Acquired By ClinActiv Holdings

    06
  7. May 14, 2026 · 10:55 · 4503 · Routine +

    GT Biopharma Advances Pipeline with First Patient Dosing, Yet Lacks Valuation Validation Amidst Peer M&A Surge

    "Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

    07
  8. May 14, 2026 · 08:30 · MBIO · Routine +

    MindBio Pivots from Failed Psychedelic Trial to AI Voice Detection Amidst Dilution Concerns

    MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Harnesses Key AI, Voice Analysis to Offer Impairment Solution

    08
  9. May 14, 2026 · 08:30 · 4151 · Routine +

    Kyowa Kirin Expands CRYSVITA Dosing Flexibility Amidst Pipeline Momentum

    FDA Approves New Dosing Option for CRYSVITA(TM) (burosumab-twza) in Adults With XLH

    09
  10. May 14, 2026 · 08:30 · SURE · Routine +

    SureNano’s GLP-1 Dreams Get Media Splash, But Stock Still Trades Below Financing Strike

    SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Developing Distinct Next-Gen GLP-1 Built Around Novel Peptide

    10
  11. May 14, 2026 · 08:01 · MBX · Routine −

    Microbix Revenue Plunges on China Sales Collapse; Cash Burn Concerns Mount Despite Q2 Stabilization

    Microbix Reports Results for H1 & Q2 2026

    11
  12. May 14, 2026 · 08:00 · 4543 · Routine +

    Strategic Integration of OrganOx Signals Portfolio Expansion

    OrganOx Announces Appointment of Naoya Iwata as CEO & President

    12
  13. May 14, 2026 · 07:31 · BPC · Neutral

    Media appearance underscores needle-free patch ambitions, but revenue from MMA deal remains the real catalyst.

    The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey

    13
  14. May 14, 2026 · 07:30 · BCT · Routine +

    Manufacturing Milestone Achieved for Prostate Candidate

    BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+(TM) for Prostate Cancer

    14
← Newer Older →